PrintThe Burrill Report
The Burrill Report (January 20, 2014): Regenerative Medicine Gets Ready for Prime Time (.MP3,18.12 Mb)
Regenerative medicine companies raised more than $1.3 billion dollars during 2013 and an expanding range of products continues to advance in the clinic. We spoke to Geoff MacKay, chairman of the Alliance for Regenerative Medicine, about the state of the industry, the growing success of the sector, and how investors and Big Pharma have changed their view of these technologies.
January 16, 2014
http://www.burrillreport.com/article-regenerative_medicine_gets_ready_for_prime_time_.html
REGENERATIVE MEDICINE / STEM CELLS
Regenerative Medicine Gets Ready for Prime Time
Podcast: January 20, 2014[Please login to post comments]
- AbbVie Terminates Shire Acquisition, But M&A; Activity Remains Brisk
Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media Read More - U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences Dealmaking
Nearly half of dollar volume of M&A; activity in 2014 involved inversions, says Burrill Media Read More - Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More - Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin. Read More - New System for Classifying Cancer Could Change the Way Drugs Are Developed
Largest cancer genetic analysis reveals tumor subtype correlated to cell type rather than tissue type. Read More - Juno Therapeutics Fills Its Coffers with Another $134M
Funding for the biotech startup in hot CAR T-cell therapy space tops $300 million. Read More
